Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ucb ADR (UCBJY)

Ucb ADR (UCBJY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 58,104,752
  • Shares Outstanding, K 378,040
  • Annual Sales, $ 6,657 M
  • Annual Income, $ 1,152 M
  • EBIT $ 0 M
  • EBITDA $ 1,598 M
  • 60-Month Beta 0.55
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 02/26/26
  • Annual Dividend & Yield (Fwd) 0.48 (0.32%)
  • Most Recent Dividend 0.483 on 04/28/25
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
135.9600 +13.05%
on 01/05/26
154.9100 -0.78%
on 01/16/26
+13.6900 (+9.78%)
since 12/16/25
3-Month
121.8000 +26.19%
on 11/03/25
154.9100 -0.78%
on 01/16/26
+4.9300 (+3.31%)
since 10/16/25
52-Week
71.1550 +116.01%
on 04/09/25
154.9100 -0.78%
on 01/16/26
+55.1650 (+55.99%)
since 01/16/25

Most Recent Stories

More News
UCB SA (0NZT) Gets a Buy from Berenberg Bank

In a report released yesterday, from Berenberg Bank maintained a Buy rating on UCB SA, with a price target of €290.00. The company’s shares closed yesterday at €258.30.Elevate Your Investing Strategy:...

UCBJF : 317.9400 (+5.10%)
UCBJY : 153.7000 (+2.34%)
Barclays Keeps Their Buy Rating on UCB SA (0NZT)

In a report released today, Charles Pitman CFA from Barclays reiterated a Buy rating on UCB SA, with a price target of €270.00. The company’s shares closed last Friday at €257.24.Elevate Your Investing...

UCBJF : 317.9400 (+5.10%)
UCBJY : 153.7000 (+2.34%)
TD Cowen Sticks to Its Buy Rating for UCB SA (0NZT)

TD Cowen analyst Stacy Ku maintained a Buy rating on UCB SA today and set a price target of €300.00. The company’s shares closed yesterday at €257.96.Elevate Your Investing Strategy: Take advantage...

UCBJF : 317.9400 (+5.10%)
UCBJY : 153.7000 (+2.34%)
Deutsche Bank Sticks to Their Buy Rating for UCB SA (0NZT)

Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on UCB SA today and set a price target of €285.00. The company’s shares closed last Friday at €250.10.Elevate Your Investing Strategy:...

UCBJF : 317.9400 (+5.10%)
UCBJY : 153.7000 (+2.34%)
Goldman Sachs Remains a Buy on UCB SA (0NZT)

Goldman Sachs analyst Rajan Sharma reiterated a Buy rating on UCB SA on September 29 and set a price target of €255.00. The company’s shares closed yesterday at €244.62.Elevate Your Investing Strategy:...

UCBJF : 317.9400 (+5.10%)
UCBJY : 153.7000 (+2.34%)
BIMZELX® (bimekizumab-bkzx) New Three-year Data in Hidradenitis Suppurativa at EADV Showed Sustained Symptom Relief Across Multiple Clinical Endpoints

ATLANTA , Sept. 17, 2025 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced three-year data from the BE HEARD trials for BIMZELX ® (bimekizumab-bkzx) in adults...

UCB : 33.86 (-0.15%)
UCBJY : 153.7000 (+2.34%)
BIMZELX® (bimekizumab-bkzx) Data in Moderate-to-Severe Plaque Psoriasis at EADV Showed Complete Skin Clearance Sustained Over Four Years

ATLANTA , Sept. 17, 2025 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced three- and four-year data from across the open-label extension (OLE) Phase 3 trials for BIMZELX...

UCB : 33.86 (-0.15%)
UCBJY : 153.7000 (+2.34%)
Gen Z and Millennial Patients with Chronic Rheumatic Diseases Are Opening Up to Raise Awareness for Improved Care

ATLANTA , Sept. 10, 2025 /PRNewswire/ -- UCB, a global biopharmaceutical company, today shared results from the "Rheum for Improvement" survey that sought to further understand unmet...

UCB : 33.86 (-0.15%)
UCBJY : 153.7000 (+2.34%)
UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress

BRUSSELS , Aug. 29, 2025 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced it will present 26 abstracts from its epilepsy portfolio at the International Epilepsy...

UCB : 33.86 (-0.15%)
UCBJF : 317.9400 (+5.10%)
UCBJY : 153.7000 (+2.34%)
UCB's HS Summit United Patients and Experts to Drive Progress in Hidradenitis Suppurativa Awareness and Treatment

ATLANTA , Aug. 5, 2025 /PRNewswire/ -- UCB, a global biopharmaceutical company, hosted its 2025 Hidradenitis Suppurativa (HS) Summit, which aimed to create a community forum for open discussion...

UCB : 33.86 (-0.15%)
UCBJY : 153.7000 (+2.34%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

UCB SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in providing therapy for central nervous system disorders, including epilepsy, diabetic neuropathic pain, sclerosis and Parkinson's disease. It also provides therapy in the areas of oncology, immunology, inflammation,...

See More

Key Turning Points

3rd Resistance Point 157.3300
2nd Resistance Point 156.1200
1st Resistance Point 154.9100
Last Price 153.7000
1st Support Level 152.4900
2nd Support Level 151.2800
3rd Support Level 150.0700

See More

52-Week High 154.9100
Last Price 153.7000
Fibonacci 61.8% 122.9156
Fibonacci 50% 113.0325
Fibonacci 38.2% 103.1494
52-Week Low 71.1550

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar